Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Tokyo, TokyoFounded 1955872 employeesWebsite
A pharmaceutical company with strengths in gastrointestinal medicine. It develops both prescription and over-the-counter products, including treatments for digestive disorders and Hepalyse.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Prescription Pharmaceuticals Business | 69% | ¥61.6B | ¥12.2B | 19.8% |
| Consumer Healthcare Business | 31% | ¥27.4B | ¥6.4B | 23.2% |
| Other Businesses | 0% | ¥151M | ¥201M | 133.1% |
Close (Oct 30, 2026)
¥1,977+1.1% (1Y)
Zeria +1.1% over 1Y, 12.0pt below the industry average (23 companies, +13.1%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥89.2B | ¥12.4B | ¥8.5B | ¥179.7B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
